Tyra Biosciences, Inc. (TYRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$21.53+0.75%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TYRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -48.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
TYRA — debt issuance
Dated 2026-09-14
Other Events. On September 14, 2026, Tyra Biosciences, Inc. (TYRA or the Company) entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of (i) 9,079,000 shares (the Shares) of the Company’s common stock, par value $0.0001 per share (the Common Stock), at…
Why it matters: SURF303 tests dabogratinib in low-grade upper tract bladder cancer. Results will show whether the study can support its planned role.
Watch forTYRA reports patient response and safety data from SURF303 at either dose. The study continues as planned.
Also watch forThe update shows little tumor response, a major safety issue, or a delay to the planned 2027 results.
Why it matters: This report can show whether cash use stays in line with the plan. TYRA reported $353.9 million in cash at June 30.
Watch forThe report shows over $300 million in cash and marketable securities. It repeats that funds should last into the second half of 2028.
Also watch forThe report shows cash below $300 million or cuts the stated runway to before the second half of 2028.
Why it matters: SURF302 is testing oral dabogratinib in bladder cancer. The results can show if the 60 mg dose has useful activity and safety.
Watch forThe full SURF302 update shows tumor responses at 60 mg and no new safety issue that blocks further study.
Also watch forThe update shows weak tumor responses at 60 mg, a safety issue, or a plan change that delays the next study.
Why it matters: The study tests dabogratinib in children with achondroplasia. Safety and height growth data will test whether the dose plan can advance.
Watch forThe update reports safety and six-month height growth at dose levels 1 through 5. It notes no notable safety events.
Also watch forThe update reports a notable safety event, weak height growth, or a delay past the end of Q1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$172 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $499 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,324 loss on $10,000 · 53.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.